US Stock Insider Trading | Lescano Pharmaceuticals Discloses One Insider Transaction on February 25

K-LinePoet · 2026-03-12T13:14:12+00:00

Lescan Pharmaceuticals Director DEBBANE RAYMOND recently conducted multiple buy transactions, including purchasing 100,000 shares on February 23, 2026, with an investment amount of approximately 147,000 USD. The company focuses on genetic research and drug development, dedicated to treating human diseases.

K-LinePoet

2026-03-12 13:14:12

Abstract generation in progress

On February 25, 2026, Lexicon Pharmaceuticals (LXRX) disclosed an insider transaction. Director DEBBANE RAYMOND purchased 100,000 shares on February 23, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 25, 2026	Director	DEBBANE RAYMOND	February 23, 2026	Buy	100,000	1.47	147,000
February 23, 2026	Director	DEBBANE RAYMOND	February 20, 2026	Buy	100,000	1.48	147,800
February 23, 2026	Director	DEBBANE RAYMOND	February 19, 2026	Buy	50,000	1.44	72,000
February 18, 2026	Director	DEBBANE RAYMOND	February 13, 2026	Buy	58,000	1.31	75,980
February 18, 2026	Director	DEBBANE RAYMOND	February 18, 2026	Buy	133,700	1.32	176,640
February 18, 2026	Director	DEBBANE RAYMOND	February 17, 2026	Buy	76,900	1.31	100,939
March 3, 2025	Executive	Alexander Kristen	February 28, 2025	Sell	17,900	0.67	11,993
March 3, 2025	Executive	McDermott Wendy	February 28, 2025	Sell	30,000	0.67	20,100
March 3, 2025	Executive	Granowitz Craig B	February 28, 2025	Sell	65,300	0.67	43,761
March 3, 2025	Main Alan J	February 28, 2025	Sell	43,400	0.67	29,078

[Company Information]

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching and achieving breakthroughs in human disease treatment. Using gene knockout technology and an advanced medical platform, the company has systematically studied the physiological and behavioral functions of nearly 5,000 genes in mice, evaluated the potential of proteins encoded by corresponding human genes as drug targets, and identified and validated over 100 targets suitable for drug discovery in vivo (or in living organisms). For targets deemed highly valuable for medicinal purposes, the company is committed to developing potential new drugs. It was incorporated in Delaware, USA, on July 7, 1995, and began operations in September 1995.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.